Trevor graduated with first-class honours in Biomedical Sciences from the University of Bristol in 2020. Following this, he worked as a COVID-19 genetic technologist, where he developed technical expertise in RT-PCR and ion semiconductor DNA sequencing. He furthered his education by completing a postgraduate master’s degree in Drug Design at University College London, earning an overall distinction and a Dean’s List nomination for his research project.
His research project aimed to harness the potential of genetic engineering, specifically focusing on transforming monoclonal antibodies into single-chain variable fragments (scFvs) – intended for use in diagnostic lateral flow assays with a primary focus on addressing a rare heritable disorder. Trevor's work extended to conducting X-ray crystallography trials and implementing in silico molecular replacement techniques to illuminate a diverse range of antibody-epitope conformations.
In addition to his academic endeavours, Trevor gained valuable intellectual property experience during a summer vacation scheme at another patent law firm in London. He further demonstrated his commitment to this field by earning a distinction for an intellectual property module as part of his master’s degree. The module brought particular focus to the role of patents, SPCs, and regulatory data protection in the commercial lifecycle of newly approved drugs.
In 2023, Trevor joined Kilburn & Strode as a Trainee Patent Attorney in the Life Sciences & Chemistry group, where he is training to become a Chartered UK and European Patent Attorney.